What did @theblacklabelclinic actually say?
The creator promoted a compounded blend of tesamorelin and ipamorelin, claiming it will "incinerate belly fat at the rate of an asteroid" and stimulate HGH and IGF-1 to fight osteoporosis, Alzheimer's, dementia, and type 2 diabetes. They argued combining the two peptides maximizes growth hormone output by hitting different receptors, reduces side effects, and saves money because you use less of each compound. Specific dosing guidance was given: roughly 0.5 mg of tesamorelin and 500 mcg to 1 mg of ipamorelin. That last part, offering specific dose ranges in a public video, is a real problem we will address below.
The cortisol angle got some attention too. The creator suggested one peptide raises cortisol while the other lowers it, so they cancel each other out. That framing deserves scrutiny.
Does the science back this up?
Tesamorelin has a real evidence base. Ipamorelin has some. The combination blend, however, is largely supported by theoretical synergy and anecdote, not controlled human trials.
Tesamorelin is FDA-approved as Egrifta for HIV-associated lipodystrophy, where it demonstrably reduces visceral adipose tissue. A pivotal trial by Falutz et al. (2010, New England Journal of Medicine) confirmed significant trunk fat reduction versus placebo. The mechanism is real: it acts as a GHRH analog, stimulating pituitary GH release.
Ipamorelin is a ghrelin mimetic and GHRP that stimulates GH through a separate receptor pathway, the GHSR. The receptor-differentiation logic the creator describes is scientifically reasonable. Raun et al. (1998, European Journal of Endocrinology) showed ipamorelin produced clean GH pulses with minimal cortisol or prolactin stimulation in animal models, which is actually one of its selling points over older GHRPs like GHRP-2.
Combining them to synergize GHRH and GHSR pathways? There is some preclinical and clinical rationale. Chapman et al. (1996, Journal of Clinical Endocrinology and Metabolism) showed GHRH plus GHRP-6 had additive GH release effects. Extrapolating that to tesamorelin plus ipamorelin is a reasonable inference, but it is not a proven fact in well-designed human trials.
What did they get wrong (or right)?
They got the receptor differentiation logic directionally right. They got the tesamorelin-visceral fat connection right. They got the cortisol claim partly wrong, and the disease-fighting framing is a serious overreach.
On cortisol: ipamorelin is specifically noted for NOT significantly raising cortisol, unlike GHRP-2 or GHRP-6. Tesamorelin studies do not prominently feature cortisol elevation as a side effect either. The creator's framing that one raises cortisol and one counteracts it is not well-supported and appears to conflate ipamorelin with other GHRPs.
The bigger problem is the disease claim. Saying this blend will "fight against" Alzheimer's, dementia, osteoporosis, and type 2 diabetes is not backed by clinical evidence for this specific product or combination. GH axis dysregulation is associated with some of these conditions, but association is not causation, and stimulating GH does not equal treating these diseases. That framing crosses a line from education into unsubstantiated medical claims.
Providing specific doses in a public video with no individual patient context is also inappropriate, regardless of whether those doses are within ranges used in research settings.
What should you actually know?
Tesamorelin is a real, studied compound with FDA-approved indications. Ipamorelin is a relatively clean GHRP with a reasonable safety profile in research contexts. But "relatively clean" and "FDA-approved for one population" does not mean safe or effective for general use as a fat-loss tool.
Compounded peptide blends sold outside of a licensed clinical relationship are not FDA-approved products. Quality, sterility, and accurate dosing in compounded preparations vary significantly. The FDA has issued repeated guidance on the risks of compounded peptides, particularly those classified as biologic drugs.
Anyone genuinely interested in peptide therapy should be evaluated by a licensed provider who can assess their baseline GH axis function, contraindications (active malignancy is a major one for GH-stimulating agents), and individual goals. Self-dosing based on a TikTok video is not a clinical protocol. If you want to explore whether tesamorelin or ipamorelin is appropriate for you, that conversation starts with a provider, not a comment section.
Bottom line on this video
The creator clearly knows something about peptide pharmacology. The receptor-synergy argument has a basis in the literature, and tesamorelin's fat-reduction data is real. But "incinerate belly fat" combined with claims about Alzheimer's and dementia prevention, public dose guidance, and no medical disclaimers makes this video more of a sales pitch than science communication. The science here is selectively cited to support a product sale, not to give viewers an accurate risk-benefit picture.